Does the media favor SMMT or KNSA?

In the previous week, Summit Therapeutics and Summit Therapeutics both had 2 articles in the media. Kiniksa Pharmaceuticals International's average media sentiment score of 0.71 beat Summit Therapeutics' score of 0.36 indicating that Kiniksa Pharmaceuticals International is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Summit Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Kiniksa Pharmaceuticals International 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Kiniksa Pharmaceuticals International (KNSA) Competitors

$79.78 +1.03 (+1.31%)

Closing price 04:00 PM Eastern

Extended Trading

$79.79 +0.01 (+0.01%)

As of 07:30 PM Eastern

Compare

KNSA vs. GMAB, EXEL, ASND, SMMT, and BBIO

Should you buy Kiniksa Pharmaceuticals International stock or one of its competitors? Kiniksa Pharmaceuticals International's main competitors and comparable companies include Genmab A/S (GMAB), Exelixis (EXEL), Ascendis Pharma A/S (ASND), Summit Therapeutics (SMMT), and BridgeBio Pharma (BBIO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Kiniksa Pharmaceuticals International compare to Genmab A/S?

Genmab A/S (NASDAQ:GMAB) and Kiniksa Pharmaceuticals International (NASDAQ:KNSA) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, valuation, institutional ownership, dividends, risk, media sentiment, analyst recommendations and earnings.

7.1% of Genmab A/S shares are held by institutional investors. Comparatively, 54.0% of Kiniksa Pharmaceuticals International shares are held by institutional investors. 1.5% of Genmab A/S shares are held by insiders. Comparatively, 52.0% of Kiniksa Pharmaceuticals International shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Genmab A/S had 26 more articles in the media than Kiniksa Pharmaceuticals International. MarketBeat recorded 28 mentions for Genmab A/S and 2 mentions for Kiniksa Pharmaceuticals International. Kiniksa Pharmaceuticals International's average media sentiment score of 0.71 beat Genmab A/S's score of 0.19 indicating that Kiniksa Pharmaceuticals International is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Genmab A/S	4 Very Positive mention(s)	7 Positive mention(s)	7 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral
Kiniksa Pharmaceuticals International	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Genmab A/S currently has a consensus target price of $42.50, indicating a potential upside of 14.65%. Kiniksa Pharmaceuticals International has a consensus target price of $93.14, indicating a potential upside of 16.75%. Given Kiniksa Pharmaceuticals International's stronger consensus rating and higher probable upside, analysts clearly believe Kiniksa Pharmaceuticals International is more favorable than Genmab A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genmab A/S	0 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.85
Kiniksa Pharmaceuticals International	0 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.89

Genmab A/S has a beta of 0.81, indicating that its share price is 19% less volatile than the broader market. Comparatively, Kiniksa Pharmaceuticals International has a beta of 0.04, indicating that its share price is 96% less volatile than the broader market.

Genmab A/S has higher revenue and earnings than Kiniksa Pharmaceuticals International. Genmab A/S is trading at a lower price-to-earnings ratio than Kiniksa Pharmaceuticals International, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genmab A/S	$3.72B	6.22	$963M	$1.27	29.19
Kiniksa Pharmaceuticals International	$677.56M	9.19	$59.01M	$0.97	82.25

Genmab A/S has a net margin of 19.08% compared to Kiniksa Pharmaceuticals International's net margin of 9.59%. Genmab A/S's return on equity of 14.89% beat Kiniksa Pharmaceuticals International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genmab A/S	19.08%	14.89%	7.73%
Kiniksa Pharmaceuticals International	9.59%	13.65%	10.09%

Summary

Genmab A/S beats Kiniksa Pharmaceuticals International on 9 of the 17 factors compared between the two stocks.

How does Kiniksa Pharmaceuticals International compare to Exelixis?

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) and Exelixis (NASDAQ:EXEL) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, dividends, earnings, institutional ownership, risk and profitability.

Exelixis has higher revenue and earnings than Kiniksa Pharmaceuticals International. Exelixis is trading at a lower price-to-earnings ratio than Kiniksa Pharmaceuticals International, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kiniksa Pharmaceuticals International	$677.56M	9.19	$59.01M	$0.97	82.25
Exelixis	$2.32B	6.39	$782.57M	$3.18	18.82

Exelixis has a net margin of 35.33% compared to Kiniksa Pharmaceuticals International's net margin of 9.59%. Exelixis' return on equity of 42.17% beat Kiniksa Pharmaceuticals International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kiniksa Pharmaceuticals International	9.59%	13.65%	10.09%
Exelixis	35.33%	42.17%	31.76%

Kiniksa Pharmaceuticals International currently has a consensus target price of $93.14, indicating a potential upside of 16.75%. Exelixis has a consensus target price of $50.79, indicating a potential downside of 15.16%. Given Kiniksa Pharmaceuticals International's stronger consensus rating and higher possible upside, analysts plainly believe Kiniksa Pharmaceuticals International is more favorable than Exelixis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kiniksa Pharmaceuticals International	0 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.89
Exelixis	1 Sell rating(s)	12 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.35

54.0% of Kiniksa Pharmaceuticals International shares are owned by institutional investors. Comparatively, 85.3% of Exelixis shares are owned by institutional investors. 52.0% of Kiniksa Pharmaceuticals International shares are owned by insiders. Comparatively, 2.6% of Exelixis shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Exelixis had 12 more articles in the media than Kiniksa Pharmaceuticals International. MarketBeat recorded 14 mentions for Exelixis and 2 mentions for Kiniksa Pharmaceuticals International. Kiniksa Pharmaceuticals International's average media sentiment score of 0.71 beat Exelixis' score of 0.34 indicating that Kiniksa Pharmaceuticals International is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kiniksa Pharmaceuticals International	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Exelixis	5 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Kiniksa Pharmaceuticals International has a beta of 0.04, indicating that its share price is 96% less volatile than the broader market. Comparatively, Exelixis has a beta of 0.47, indicating that its share price is 53% less volatile than the broader market.

Summary

Exelixis beats Kiniksa Pharmaceuticals International on 10 of the 17 factors compared between the two stocks.

How does Kiniksa Pharmaceuticals International compare to Ascendis Pharma A/S?

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) and Ascendis Pharma A/S (NASDAQ:ASND) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, valuation, analyst recommendations, media sentiment and dividends.

In the previous week, Ascendis Pharma A/S had 1 more articles in the media than Kiniksa Pharmaceuticals International. MarketBeat recorded 3 mentions for Ascendis Pharma A/S and 2 mentions for Kiniksa Pharmaceuticals International. Kiniksa Pharmaceuticals International's average media sentiment score of 0.71 beat Ascendis Pharma A/S's score of 0.33 indicating that Kiniksa Pharmaceuticals International is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kiniksa Pharmaceuticals International	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ascendis Pharma A/S	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Kiniksa Pharmaceuticals International has higher earnings, but lower revenue than Ascendis Pharma A/S. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than Kiniksa Pharmaceuticals International, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kiniksa Pharmaceuticals International	$677.56M	9.19	$59.01M	$0.97	82.25
Ascendis Pharma A/S	$814.57M	17.55	-$258M	$12.89	17.78

Ascendis Pharma A/S has a net margin of 70.99% compared to Kiniksa Pharmaceuticals International's net margin of 9.59%. Ascendis Pharma A/S's return on equity of 32.54% beat Kiniksa Pharmaceuticals International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kiniksa Pharmaceuticals International	9.59%	13.65%	10.09%
Ascendis Pharma A/S	70.99%	32.54%	7.71%

Kiniksa Pharmaceuticals International presently has a consensus price target of $93.14, suggesting a potential upside of 16.75%. Ascendis Pharma A/S has a consensus price target of $313.21, suggesting a potential upside of 36.64%. Given Ascendis Pharma A/S's stronger consensus rating and higher possible upside, analysts plainly believe Ascendis Pharma A/S is more favorable than Kiniksa Pharmaceuticals International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kiniksa Pharmaceuticals International	0 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.89
Ascendis Pharma A/S	0 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	3.00

Kiniksa Pharmaceuticals International has a beta of 0.04, meaning that its share price is 96% less volatile than the broader market. Comparatively, Ascendis Pharma A/S has a beta of 0.38, meaning that its share price is 62% less volatile than the broader market.

54.0% of Kiniksa Pharmaceuticals International shares are owned by institutional investors. 52.0% of Kiniksa Pharmaceuticals International shares are owned by company insiders. Comparatively, 40.0% of Ascendis Pharma A/S shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Ascendis Pharma A/S beats Kiniksa Pharmaceuticals International on 11 of the 17 factors compared between the two stocks.

How does Kiniksa Pharmaceuticals International compare to Summit Therapeutics?

Summit Therapeutics (NASDAQ:SMMT) and Kiniksa Pharmaceuticals International (NASDAQ:KNSA) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, dividends, media sentiment, risk, valuation, profitability, analyst recommendations and institutional ownership.

Kiniksa Pharmaceuticals International has higher revenue and earnings than Summit Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than Kiniksa Pharmaceuticals International, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.12	N/A
Kiniksa Pharmaceuticals International	$677.56M	9.19	$59.01M	$0.97	82.25

4.6% of Summit Therapeutics shares are owned by institutional investors. Comparatively, 54.0% of Kiniksa Pharmaceuticals International shares are owned by institutional investors. 83.5% of Summit Therapeutics shares are owned by insiders. Comparatively, 52.0% of Kiniksa Pharmaceuticals International shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summit Therapeutics has a beta of -1.51, indicating that its share price is 251% less volatile than the broader market. Comparatively, Kiniksa Pharmaceuticals International has a beta of 0.04, indicating that its share price is 96% less volatile than the broader market.

Summit Therapeutics presently has a consensus price target of $28.61, suggesting a potential upside of 62.64%. Kiniksa Pharmaceuticals International has a consensus price target of $93.14, suggesting a potential upside of 16.75%. Given Summit Therapeutics' higher possible upside, equities analysts clearly believe Summit Therapeutics is more favorable than Kiniksa Pharmaceuticals International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Summit Therapeutics	1 Sell rating(s)	8 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.53
Kiniksa Pharmaceuticals International	0 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.89

Kiniksa Pharmaceuticals International has a net margin of 9.59% compared to Summit Therapeutics' net margin of 0.00%. Kiniksa Pharmaceuticals International's return on equity of 13.65% beat Summit Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Summit Therapeutics	N/A	-168.94%	-141.92%
Kiniksa Pharmaceuticals International	9.59%	13.65%	10.09%

In the previous week, Summit Therapeutics and Summit Therapeutics both had 2 articles in the media. Kiniksa Pharmaceuticals International's average media sentiment score of 0.71 beat Summit Therapeutics' score of 0.36 indicating that Kiniksa Pharmaceuticals International is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Summit Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Kiniksa Pharmaceuticals International	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Kiniksa Pharmaceuticals International beats Summit Therapeutics on 11 of the 15 factors compared between the two stocks.

How does Kiniksa Pharmaceuticals International compare to BridgeBio Pharma?

BridgeBio Pharma (NASDAQ:BBIO) and Kiniksa Pharmaceuticals International (NASDAQ:KNSA) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, dividends, valuation, media sentiment, earnings, analyst recommendations and profitability.

BridgeBio Pharma presently has a consensus target price of $105.42, suggesting a potential upside of 61.32%. Kiniksa Pharmaceuticals International has a consensus target price of $93.14, suggesting a potential upside of 16.75%. Given BridgeBio Pharma's higher possible upside, equities analysts clearly believe BridgeBio Pharma is more favorable than Kiniksa Pharmaceuticals International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	21 Buy rating(s)	0 Strong Buy rating(s)	2.83
Kiniksa Pharmaceuticals International	0 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.89

99.9% of BridgeBio Pharma shares are held by institutional investors. Comparatively, 54.0% of Kiniksa Pharmaceuticals International shares are held by institutional investors. 14.2% of BridgeBio Pharma shares are held by company insiders. Comparatively, 52.0% of Kiniksa Pharmaceuticals International shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

BridgeBio Pharma has a beta of 0.97, suggesting that its stock price is 3% less volatile than the broader market. Comparatively, Kiniksa Pharmaceuticals International has a beta of 0.04, suggesting that its stock price is 96% less volatile than the broader market.

Kiniksa Pharmaceuticals International has higher revenue and earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Kiniksa Pharmaceuticals International, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BridgeBio Pharma	$502.08M	25.44	-$724.93M	-$3.57	N/A
Kiniksa Pharmaceuticals International	$677.56M	9.19	$59.01M	$0.97	82.25

Kiniksa Pharmaceuticals International has a net margin of 9.59% compared to BridgeBio Pharma's net margin of -97.03%. Kiniksa Pharmaceuticals International's return on equity of 13.65% beat BridgeBio Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BridgeBio Pharma	-97.03%	N/A	-61.19%
Kiniksa Pharmaceuticals International	9.59%	13.65%	10.09%

In the previous week, BridgeBio Pharma had 11 more articles in the media than Kiniksa Pharmaceuticals International. MarketBeat recorded 13 mentions for BridgeBio Pharma and 2 mentions for Kiniksa Pharmaceuticals International. Kiniksa Pharmaceuticals International's average media sentiment score of 0.71 beat BridgeBio Pharma's score of 0.49 indicating that Kiniksa Pharmaceuticals International is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BridgeBio Pharma	3 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Kiniksa Pharmaceuticals International	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Kiniksa Pharmaceuticals International beats BridgeBio Pharma on 10 of the 16 factors compared between the two stocks.

Get Kiniksa Pharmaceuticals International News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KNSA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KNSA vs. The Competition

Export

Metric	Kiniksa Pharmaceuticals International	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$6.14B	$3.84B	$7.16B	$13.21B
Dividend Yield	N/A	3.66%	2.53%	20.71%
P/E Ratio	82.25	13.42	274.13	26.16
Price / Sales	9.19	1,237.44	589.97	95.24
Price / Cash	99.21	116.56	76.38	53.09
Price / Book	10.72	17.17	11.21	6.34
Net Income	$59.01M	-$22.69M	$3.50B	$381.90M
7 Day Performance	5.26%	-1.20%	-0.84%	-1.39%
1 Month Performance	1.60%	-9.68%	-5.42%	-4.31%
1 Year Performance	109.34%	10.09%	4.38%	-0.35%

Kiniksa Pharmaceuticals International Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KNSA Kiniksa Pharmaceuticals International	4.0578 of 5 stars	$79.78 +1.3%	$93.14 +16.7%	+105.6%	$6.14B	$677.56M	82.25	366	Analyst Upgrade
GMAB Genmab A/S	4.0679 of 5 stars	$34.55 -3.1%	$39.50 +14.3%	+10.1%	$21.56B	$3.72B	27.20	3,029	Analyst Forecast Analyst Revision High Trading Volume
EXEL Exelixis	2.4643 of 5 stars	$57.94 -0.8%	$50.29 -13.2%	+52.7%	$14.36B	$2.32B	18.22	1,077	Trending News Analyst Forecast Analyst Revision
ASND Ascendis Pharma A/S	4.7897 of 5 stars	$227.31 -0.2%	$310.75 +36.7%	+6.0%	$14.18B	$814.57M	17.63	1,189
SMMT Summit Therapeutics	2.3488 of 5 stars	$16.69 -1.3%	$28.61 +71.4%	-26.4%	$13.31B	N/A	N/A	265

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:KNSA) was last updated on 10/9/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Kiniksa Pharmaceuticals International (KNSA) Competitors

KNSA vs. GMAB, EXEL, ASND, SMMT, and BBIO

How does Kiniksa Pharmaceuticals International compare to Genmab A/S?

Summary

How does Kiniksa Pharmaceuticals International compare to Exelixis?

Summary

How does Kiniksa Pharmaceuticals International compare to Ascendis Pharma A/S?

Summary

How does Kiniksa Pharmaceuticals International compare to Summit Therapeutics?

Summary

How does Kiniksa Pharmaceuticals International compare to BridgeBio Pharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KNSA vs. The Competition

Kiniksa Pharmaceuticals International Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Kiniksa Pharmaceuticals International (KNSA) Competitors

KNSA vs. GMAB, EXEL, ASND, SMMT, and BBIO

How does Kiniksa Pharmaceuticals International compare to Genmab A/S?

Do institutionals & insiders believe in GMAB or KNSA?

Does the media refer more to GMAB or KNSA?

Do analysts recommend GMAB or KNSA?

Which has more volatility and risk, GMAB or KNSA?

Which has higher valuation & earnings, GMAB or KNSA?

Is GMAB or KNSA more profitable?

Summary

How does Kiniksa Pharmaceuticals International compare to Exelixis?

Which has stronger earnings and valuation, KNSA or EXEL?

Is KNSA or EXEL more profitable?

Do analysts recommend KNSA or EXEL?

Do institutionals and insiders believe in KNSA or EXEL?

Does the media refer more to KNSA or EXEL?

Which has more risk & volatility, KNSA or EXEL?

Summary

How does Kiniksa Pharmaceuticals International compare to Ascendis Pharma A/S?

Does the media refer more to KNSA or ASND?

Which has higher valuation & earnings, KNSA or ASND?

Is KNSA or ASND more profitable?

Do analysts rate KNSA or ASND?

Which has more risk and volatility, KNSA or ASND?

Do institutionals and insiders have more ownership in KNSA or ASND?

Summary

How does Kiniksa Pharmaceuticals International compare to Summit Therapeutics?

Which has higher earnings & valuation, SMMT or KNSA?

Do insiders & institutionals hold more shares of SMMT or KNSA?

Which has more risk & volatility, SMMT or KNSA?

Do analysts rate SMMT or KNSA?

Is SMMT or KNSA more profitable?

Does the media favor SMMT or KNSA?

Summary

How does Kiniksa Pharmaceuticals International compare to BridgeBio Pharma?

Do analysts prefer BBIO or KNSA?

Do institutionals and insiders have more ownership in BBIO or KNSA?

Which has more risk & volatility, BBIO or KNSA?

Which has higher valuation and earnings, BBIO or KNSA?

Is BBIO or KNSA more profitable?

Does the media prefer BBIO or KNSA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KNSA vs. The Competition

Kiniksa Pharmaceuticals International Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools